Literature DB >> 25382300

Toll-like receptor agonist lipopeptides self-assemble into distinct nanostructures.

Ian W Hamley1, Steven Kirkham, Ashkan Dehsorkhi, Valeria Castelletto, Mehedi Reza, Janne Ruokolainen.   

Abstract

The self-assembled structure of toll-like receptor agonist lipopeptides containing the CSK4 peptide sequence is examined in aqueous solution. A remarkable dependence of morphology on the number of attached hexadecyl lipid chains is demonstrated, with spherical micelle structures for mono- and di-lipidated structures observed, but flexible wormlike micelles for the homologue containing three lipid chains. The distinct modes of assembly may have an important influence on the bioactivity of this class of lipopeptide.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25382300     DOI: 10.1039/c4cc07511k

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  11 in total

1.  Toll-Like Receptor 2 Ligation Enhances HIV-1 Replication in Activated CCR6+ CD4+ T Cells by Increasing Virus Entry and Establishing a More Permissive Environment to Infection.

Authors:  Jean-François Bolduc; Michel Ouellet; Laurent Hany; Michel J Tremblay
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.

Authors:  Arshpreet Kaur; Sakshi Piplani; Deepender Kaushik; Johnson Fung; Isaac G Sakala; Yoshikazu Honda-Okubo; Surinder K Mehta; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2022-04-20

Review 3.  Guiding principles in the design of molecular bioconjugates for vaccine applications.

Authors:  Haipeng Liu; Darrell J Irvine
Journal:  Bioconjug Chem       Date:  2015-04-16       Impact factor: 4.774

4.  Receptor-Ligand Kinetics Influence the Mechanism of Action of Covalently Linked TLR Ligands.

Authors:  Flora W Kimani; Jainu Ajit; Alexander Galluppi; Saikat Manna; William J Howitz; Sophia Tang; Aaron P Esser-Kahn
Journal:  ACS Chem Biol       Date:  2021-02-01       Impact factor: 5.100

Review 5.  Peptide hormones and lipopeptides: from self-assembly to therapeutic applications.

Authors:  J A Hutchinson; S Burholt; I W Hamley
Journal:  J Pept Sci       Date:  2017-01-27       Impact factor: 1.905

6.  Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune Responses.

Authors:  Tyler J Albin; Janine K Tom; Saikat Manna; Adrienne P Gilkes; Samuel A Stetkevich; Benjamin B Katz; Medalyn Supnet; Jiin Felgner; Aarti Jain; Rie Nakajima; Algis Jasinskas; Albert Zlotnik; Eric Pearlman; D Huw Davies; Phillip L Felgner; Amanda M Burkhardt; Aaron P Esser-Kahn
Journal:  ACS Cent Sci       Date:  2019-06-27       Impact factor: 14.553

7.  Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering.

Authors:  Michael H Zhang; Emily M Slaby; Georgina Stephanie; Chunsong Yu; Darcy M Watts; Haipeng Liu; Gregory L Szeto
Journal:  Front Immunol       Date:  2020-04-22       Impact factor: 7.561

8.  Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.

Authors:  Simon Megy; Stephanie Aguero; David Da Costa; Myriam Lamrayah; Morgane Berthet; Charlotte Primard; Bernard Verrier; Raphael Terreux
Journal:  Nanomaterials (Basel)       Date:  2020-11-05       Impact factor: 5.076

9.  Physicochemical Characterization of Daptomycin Interaction with Negatively Charged Lipid Membranes.

Authors:  Joanna Juhaniewicz-Dębińska; Damian Dziubak; Sławomir Sęk
Journal:  Langmuir       Date:  2020-05-07       Impact factor: 3.882

10.  High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation.

Authors:  Adam J R Gadd; Valeria Castelletto; Elena Kabova; Kenneth Shankland; Yvonne Perrie; Ian Hamley; Alexander J A Cobb; F Greco; Alexander D Edwards
Journal:  Eur J Pharm Sci       Date:  2018-07-24       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.